# US 2025/0062038 A1 · METHOD OF DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-COVID (SARS-CoV)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0062038 A1
- Document ID: US20250062038A1
- Status: Published application
- Kind: A1
- Application number: 18/451,410
- Filed: 2023-08-17
- Published: 2025-02-20
- Earliest claimed: 2023-08-17
- Assignees: King Fahd University of Petroleum and Minerals
- Applicants: King Fahd University of Petroleum and Minerals
- Inventors: Amjad Bajes KHALIL; Muhammad NAEEM; Hanoof Fahad ALKHODAIRY; Aasif HELAL
- Web page: https://patentgrep.com/patent/US20250062038A1

## CPC

- G16H 50/80: for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
- G01N 33/582: {with fluorescent label}
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of detecting SARS-COV in a sample includes contacting a metal-organic framework with at least one fluorophore-labeled single-stranded probe deoxyribose nucleic acid (DNA) to form a biosensor. The metal-organic framework of the method is zeolitic imidazolate framework-8 (ZIF-8), and the fluorophore-labeled single-stranded probe DNA (p-DNA) has a fluorescence signal at 513 to 517 nm. The method further includes contacting the sample with the biosensor in a solution, and the sample comprises a target sequence of SARS-COV. The target sequence of SARS-COV and the fluorophore-labeled single-stranded p-DNA of the method hybridize to form a double-stranded product. Following the step of the hybridization forming the double-stranded product, the method includes detecting the double-stranded product by observing a change in fluorescence.

## Claims

### Claim at position 1

1: A method of detecting SARS-COV in a sample, comprising:
contacting a metal-organic framework with at least one fluorophore-labeled single-stranded probe deoxyribose nucleic acid (DNA) to form a biosensor,
wherein the metal-organic framework is zeolitic imidazolate framework-8 (ZIF-8),
wherein the fluorophore-labeled single-stranded probe DNA has a fluorescence signal at 513 to 517 nm in the absence of the ZIF-8,
wherein the fluorophore-labeled single-stranded probe DNA docks with the metal-organic framework through attractive noncovalent π-orbital overlaps,
wherein the biosensor is fluorescently inactive,
contacting the sample with the biosensor in a solution,
wherein the sample comprises a target sequence of SARS-COV,
wherein the target sequence of SARS-COV and the fluorophore-labeled single-stranded probe DNA hybridize to form a double-stranded product,
detecting the double-stranded product by observing a change in fluorescence,
wherein the change in fluorescence is a re-emergent fluorescence signal at 513 to 517 nm of the fluorophore-labeled single-stranded probe DNA,
wherein the re-emergent fluorescence signal at 513 to 517 nm of the fluorophore-labeled single-stranded probe DNA indicates the presence of SARS-COV in the sample, thereby detecting SARS-COV in the sample.

### Claim at position 2 (depends on 1)

2: The method of claim 1, wherein the fluorophore-labeled single-stranded probe DNA is 100 percent complementary to the target sequence of SARS-COV.

### Claim at position 3 (depends on 1)

3: The method of claim 1, wherein a fluorophore of the fluorophore-labeled single-stranded probe DNA is a carboxyfluorescein.

### Claim at position 4 (depends on 3)

4: The method of claim 3, wherein the carboxyfluorescein is a 6-carboxyfluorescein moiety.

### Claim at position 5 (depends on 3)

5: The method of claim 3, wherein the fluorophore of the fluorophore-labeled single-stranded probe DNA is tagged at a 5′ end of the fluorophore-labeled single-stranded probe DNA.

### Claim at position 6 (depends on 1)

6: The method of claim 1, wherein the target sequence of SARS-COV is an RNA target sequence.

### Claim at position 7 (depends on 1)

7: The method of claim 1, wherein the target sequence of SARS-COV is a conserved sequence.

### Claim at position 8 (depends on 1)

8: The method of claim 1, wherein the SARS-COV is SARS-COV-2.

### Claim at position 9 (depends on 1)

9: The method of claim 1, wherein the ZIF-8 comprises zinc and 2-methylimidazole and was synthesized at room temperature with an at least 75% yield based on a starting weight of a zinc salt and 2-methylimidazole.

### Claim at position 10 (depends on 1)

10: The method of claim 1, wherein the ZIF-8 has a thermogravimetric analysis stability of up to 510° C.

### Claim at position 11 (depends on 1)

11: The method of claim 1, wherein a lower limit of detection of the SARS-COV is a concentration of 200 pM of the target sequence of SARS-COV in the sample.

### Claim at position 12 (depends on 1)

12: The method of claim 1, wherein the solution comprises a TAE buffer comprising:
a tris(hydroxymethyl)aminomethane base;
an acetic acid, and
an ethylenediaminetetraacetic acid.

### Claim at position 13 (depends on 1)

13: The method of claim 1, wherein the fluorophore-labeled single-stranded probe DNA docks with the metal-organic framework through attractive noncovalent I-orbital overlaps of at least one imidazole the 2-methylimidazole of the metal-organic framework and at least one fluorophore of the fluorophore-labeled single-stranded probe DNA.

### Claim at position 14 (depends on 1)

14: The method of claim 1, wherein a ratio of the fluorophore-labeled single-stranded probe DNA to the ZIF-8 in the biosensor is from 1:10 to 1:50 by weight.

### Claim at position 15 (depends on 1)

15: The method of claim 1, wherein the re-emergent fluorescence signal at 513 to 517 nm of the fluorophore-labeled single-stranded probe DNA is at least 90% of an initial fluorescence signal at 513 to 517 nm of the fluorophore-labeled single-stranded probe DNA in the absence of the ZIF-8.

### Claim at position 16 (depends on 1)

16: The method of claim 1, wherein the contacting the sample with the biosensor in the solution is at a temperature of 0 to 10° C.

### Claim at position 17 (depends on 1)

17: The method of claim 1, wherein the contacting the sample with the biosensor in the solution occurs for a time of 20 to 40 minutes.

### Claim at position 18 (depends on 1)

18: The method of claim 1, wherein the target sequence of SARS-COV is at least 85% complementary to the fluorophore-labeled single-stranded probe DNA and the re-emergent fluorescence signal at 513 to 517 nm of the fluorophore-labeled single-stranded probe DNA is from 15 to 95% of an initial fluorescence signal at 513 to 517 nm of the fluorophore-labeled single-stranded probe DNA in the absence of the ZIF-8.

### Claim at position 19 (depends on 1)

19: The method of claim 1, wherein fluorophore-labeled single-stranded probe DNA comprises SEQ ID NO.: 1.

### Claim at position 20 (depends on 1)

20: The method of claim 1, further comprising:
detecting one or more RNA viruses and one or more DNA viruses in the sample.
